Published online April 2, 2007
PEDIATRICS Vol. 119 No. 4 April 2007, pp. e798-e803 (doi:10.1542/peds.2006-1384)
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raymond, J.
Right arrow Articles by Aujard, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raymond, J.
Right arrow Articles by Aujard, Y.
Related Collections
Right arrow Infectious Disease & Immunity

ARTICLE

Multidrug-Resistant Bacteria in Hospitalized Children: A 5-Year Multicenter Study

Josette Raymond, MD, PhDa, Patrice Nordmann, MD, PhDb, Catherine Doit, MDc, Hoang Vu Thien, MDd, Michèle Guibert, MDe, Agnès Ferroni, MDf and Yannick Aujard, MDg

a Service de Bactériologie, Hôpital Cochin-Saint Vincent de Paul, Paris, France
b Service de Microbiologie, Hôpital de Bicêtre, Kremlin-Bicêtre, France
c Service de Microbiologie
g Service de Néonatologie, Hôpital Robert Debré, Paris, France
d Service de Microbiologie, Hôpital Trousseau, Paris, France
e Service de Microbiologie, Hôpital Antoine Béclère, Clamart, France
f Service de Microbiologie, Hôpital Necker Enfants-Malades, Paris, France


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 CONCLUSIONS
 REFERENCES
 
OBJECTIVE. The objective of this study was to determine the incidence of multidrug-resistant bacteria in hospitalized children

METHODS. This multicenter study was conducted in 5 hospitals in the Paris area from 1999 to 2003. We recorded all isolations of multidrug-resistant bacteria from clinical samples that were obtained from hospitalized children. Strains that were isolated during systematic screening for carriers were excluded.

RESULTS. The mean incidences were 0.9 per 1000 hospitalization-days for methicillin-resistant Staphylococcus aureus, 0.45 for extended-spectrum ß-lactamase–producing Klebsiella pneumoniae, 0.32 for extended-spectrum ß-lactamase–producing Enterobacteriaceae other than Klebsiella pneumoniae, 0.40 for Enterobacter species with derepressed cephalosporinase, and 0.01 for vancomycin-resistant Enterococcus. The incidences per 1000 hospitalization-days of methicillin-resistant Staphylococcus aureus, extended-spectrum ß-lactamase–producing Klebsiella pneumoniae, extended-spectrum ß-lactamase–producing Enterobacteriaceae other than Klebsiella pneumoniae, and Enterobacter species with derepressed cephalosporinase decreased significantly from 1999 to 2003, whereas the incidence of vancomycin-resistant Enterococcus remained very low. The proportion of resistant strains within the species did not vary significantly for methicillin-resistant Staphylococcus aureus (11% to 9.6%), extended-spectrum ß-lactamase–producing Enterobacteriaceae other than Klebsiella pneumoniae (1.1%), and vancomycin-resistant Enterococcus (0.03% to 0.023%). In contrast, the frequency of extended-spectrum ß-lactamase–producing Klebsiella pneumoniae decreased from 31.6% to 7.4%, and that of Enterobacter species with derepressed cephalosporinase decreased from 38.8% to 18.5%.

CONCLUSIONS. We report significant decreases in the incidence of methicillin-resistant Staphylococcus aureus, extended-spectrum ß-lactamase–producing Klebsiella pneumoniae, extended-spectrum ß-lactamase–producing Enterobacteriaceae other than Klebsiella pneumoniae, and Enterobacter species with derepressed cephalosporinase in hospitalized children during a 5-year period.

Key Words: multidrug-resistant bacteria • children • nosocomial infections

Abbreviations: MDRB—multidrug-resistant bacteria • MRSA—methicillin-resistant Staphylococcus aureus • VRE—vancomycin-resistant Enterococcus • ESBL—extended-spectrum ß-lactamase • ESBLKp—extended-spectrum ß-lactamase–producing Klebsiella pneumoniae • UTI—urinary tract infection • ESBLE—extended-spectrum ß-lactamase–producing Enterobacteriaceae other than K pneumoniae • HD—hospitalization-days

Multidrug-resistant bacteria (MDRB) present an emerging threat worldwide in hospitalized children as in adult patients.1,2 They are responsible of an increase in mortality rate and additional financial costs.3 The most clinically relevant MDRB include methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum cephalosporin-resistant Gram-negative bacilli, and vancomycin-resistant enterococci (VRE).1 MDRB colonization occurs as a result of patient-to-patient transmission and/or the selective effects of antimicrobial therapy.4 MDRB colonization/infection can be used as an indicator of compliance with hygiene measures.

Incidence of MDRB is widely known in hospitalized adults. MRSA strains accounted for 5% to 20% of the S aureus that was isolated from adult patients who were hospitalized in ICUs in Europe5 and 64.4% of those who were isolated in similar situations in the United States in 2006.6 In Europe, >20% of the Klebsiella strains that were isolated from adult patients in ICUs were found to produce an extended-spectrum ß-lactamase (ESBL; ESBL-producing Klebsiella pneumoniae [ESBLKp]) in 19987 and often are responsible of outbreaks.8 The frequency of VRE ranges from <1% in Europe to >20% in ICUs in the United States.9 However, few data are available concerning the incidence of MDRB in hospitalized children. In a study by Cosseron et al,10 11% of the S aureus strains that were isolated from NICUs and PICUs were MRSA. Kim et al11 reported that ESBLKp strains accounted for 52.9% of the Klebsiella strains that were isolated from bacteremic patients in Korea. In a previous multicenter study that was conducted in pediatric units in 8 European countries, we found that 18% of the S aureus strains were MRSA and 14% of the Klebsiella strains were ESBLKp.2 We report the results of a multicenter study that was conducted to determine the frequency of MDRB and the incidence of infections with these bacteria in hospitalized children during a 5-year period in 5 university hospitals in the Paris area.


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 CONCLUSIONS
 REFERENCES
 
Patients
This prospective study was conducted from January 1, 1999, to December 31, 2003, by the microbiology laboratories of 5 teaching hospitals. Three of them were exclusively pediatric hospitals, with 480, 250, and 350 beds, respectively. Two other pediatric departments included, respectively, 200 and 350 pediatric beds in "mixed" hospitals that admit both children and adult patients. Five PICUs and 3 NICUs were included. All of these hospitals were part of the same network, and the French National Guidelines for Control Measures were applied at each hospital.

Nosocomial bloodstream infections, catheter-related infections, and urinary tract infections (UTIs) were defined as previously reported.12,13 Clinical signs of bacteremia, such as fever and chills, were always present. Urine was collected using sterile bags in children who were younger than 2 years.

The antimicrobial treatments that were administered before infection were not analyzed. Antibiotic treatment protocols for suspected nosocomial sepsis was a combination of vancomycin, a third-generation cephalosporin, and an aminoglycoside was given when the patient had an indwelling catheter; vancomycin was omitted from this combination for the treatment of suspected sepsis in patients without an indwelling catheter. The use of carbapenem was restricted to children who previously were identified as carriers of MDRB. These empiric treatment recommendations were maintained throughout the study and were applied in all hospitals.

Bacteria
All MRSA, ESBLKp, ESBL-producing Enterobacteriaceae other than K pneumoniae (ESBLE), Enterobacter species with derepressed cephalosporinase, and VRE that were isolated from clinical specimens in cases of suspected or confirmed infection were recorded. Only strains that were cultured from clinical samples that were taken 48 hours after admission were counted. Strains that were isolated during systematic screening for carriage were not considered. When multiple strains of the same species with the same antimicrobial susceptibility were recovered from a single patient, only the first isolate was included. We also recorded the sampling site of each strain.

We did not systematically record cases of bacteremia that was caused by non-MDRB. The overall frequency of MDRB among all bacteria that were isolated from patients with infection therefore was not known.

Infection Control Measures
The French National Guidelines for Control Measures that were published in 1999 were applied at each hospital.14 They included recommendations (1) to identify reservoirs of MDRB by systematic screening for MDRB in newly hospitalized patients; briefly, samples from nose and anus were taken at admission from patients in ICUs; (2) for the early notification of the clinician by the laboratory and notification of the new hospital if the patient is transferred (3) to prevent transmission between patients by means of barrier precautions for colonized and infected patients, such as antiseptic hand-washing, the wearing of gloves, and keeping infected patients isolated in single rooms or keeping patients who are infected with the same bacterium together in the same room; and (4) to organize systematic detection and monitoring of carriers. In case of an extended hospitalization, samples from nose and anus were taken each week to search MDRB.

Microbiologic Methods
The Kirby-Bauer disk diffusion method, microbroth dilution, and E-tests (AB Biodisk, Solna, Sweden) were performed according to National Committee for Clinical Laboratory Standards guidelines, using the recommended thresholds to define resistance.15 S aureus strains were considered to be resistant to methicillin when a diameter of inhibition of <20 mm was observed around a 5-µg oxacillin disk after 24 hours to 48 hours of incubation at 35°C. We used the double-disk synergy method to assess ESBL production in Enterobacteriaceae isolates as previously described.16 The derepression of cephalosporinase in Enterobacter (Enterobacter expressing chromosomal ampC ß-lactamases) was detected on the basis of cefotaxime resistance (minimum inhibitory concentration ≥16 µg/mL). For detection of a possible ß-lactamase, each cefotaxime-resistant Enterobacter was tested on an MH medium (Mérieux, Marcy l'Etoile, France) with 100 mg/L of cloxacillin as cephalosporinase inhibitor.15 VRE strains were detected by vancomycin and teicoplanin E-tests (AB Biodisk), conducted according to the manufacturer's instructions.

Data Analysis
We used 3 different surveillance indicators: (1) percentage of MRSA strains among isolated strains of S aureus, of ESBL Klebsiella strains among isolated Klebsiella species strains, of cefotaxime-resistant Enterobacter strains among Enterobacter species, and of VRE strains among Enterococcus species; (2) the incidence of MDRB infection per 1000 hospitalization-days (HD); and (3) the incidence of MDRB infection per 100 admissions. Changes over time in incidence per 1000 HD and per 100 admissions were analyzed from 1999 to 2003 for bacteremia, catheter-related infections, and UTI.

Statistical Analysis
Time trends were analyzed by {chi}2 tests for linear trend on proportions and goodness of fit, comparing the observed and expected incidence rate distributions. For all tests, P < .05 was considered significant.


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 CONCLUSIONS
 REFERENCES
 
During the 5-year study, 345150 admissions were recorded: 73911 in 1999, 70922 in 2000, 69299 in 2001, 69973 in 2002, and 69865 in 2003. A total of 3856 multidrug-resistant pathogens were isolated from 1999 to 2003: 1665 MRSA (10.1% of all isolated S aureus strains), 832 ESBLKp (23.2% of isolated K pneumoniae strains), 594 ESBLE (1.4%), 743 Enterobacter species with derepressed cephalosporinase (24.6% of isolated Enterobacter species), and 22 VRE (0.28% of isolated Enterococcus species; Table 1). The global incidence of MDRB was 2.8 cases per 1000 HD, corresponding to 1.4 cases per 100 admissions.


View this table:
[in this window]
[in a new window]

  		TABLE 1 Temporal Trends for MRSA, ESBLKp, ESBLE, Cefotaxime-Resistant Enterobacter, and VRE, Calculated for the 6 Centers That Participated Each Year Between 1999 and 2003

 
MDRB incidence per 1000 HD decreased during the course of the study: from 1.06 to 0.75 (mean: 0.9) for MRSA, from 0.71 to 0.12 (mean: 0.45) for ESBLKp, from 0.45 to 0.21 (mean: 0.32) for ESBL-producing Enterobacteriaceae, and from 0.74 to 0.24 (mean: 0.40) for derepressed Enterobacter species. The incidence of VRE was 0.01 per 1000 HD and 0.01 per 100 admissions (Table 1).

The percentages of MRSA, ESBLE, and VRE strains in the corresponding species did not vary significantly during the course of the study. Conversely, the proportion of ESBLKp decreased considerably, from 31.6% to 7.4% (P < .0001), and that of derepressed Enterobacter species decreased from 38.8% to 18.5% (P < .0001; Table 1).

The global incidences of MRSA, ESBLKp, ESBLE, and derepressed Enterobacter infections per 1000 HD decreased significantly from 1999 to 2003 (P < .001). Similarly, incidences per 100 admissions of ESBLKp, ESBLE, and derepressed Enterobacter infections decreased significantly during the same period except for MRSA.

Between 1999 and 2003, incidence per 100 admissions of ESBLKp decreased significantly in 3 centers but not significantly in 2 centers, probably in relation with the low number of isolated bacteria. The incidence of derepressed Enterobacter decreased significantly in 3 centers and not significantly in 2 centers; incidence of ESBLE decreased in 3 centers, increased in 1 (with a low number of isolated strains), and was stable for the last 1. Finally, global trend of MRSA incidence did not decrease because bacterial evolution was different according to the centers (Table 2).


View this table:
[in this window]
[in a new window]

  		TABLE 2 Temporal Trends of Incidence per 100 Admissions for MRSA, ESBLKp, ESBLE, and Cefotaxime-Resistant Enterobacter for Each of the 5 Centers That Participated Each Year Between 1999 and 2003

 
The incidence per 1000 HD of MDRB infection was determined as a function of the site of infection. The mean incidence of primary MDRB bacteremia was 0.11 per 1000 HD (0.12–0.08), and that of catheter-related infections was 0.08 per 1000 HD (0.1–0.06). The incidence of UTI as a result of MDRB was 0.34 per 1000 HD (0.39–0.31). The incidences of bacteremia, catheter-related infections, and UTI as a result of MDRB did not vary significantly during the study period (P = 1.0).

Of the 3856 MDRB isolated, 176 (4.6%) were responsible for primary septicemia: 88 (51.2%) MRSA, 34 (19.3%) ESBLKp, 21 (11.9%) ESBLE, and 33 (18.7%) derepressed Enterobacter species. For catheter-related infections, 119 (3%) MDRB were isolated: 52 (43.7%) MRSA, 29 (24.4%) ESBLKp, 17 (14.3%) ESBLE, and 21 (17.6%) derepressed Enterobacter. For UTI, 492 (12.8%) MDRB were isolated: 54 (11%) MRSA, 137 (27.8%) ESBLKp, 131 (26.6%) ESBLE, 170 (34.5%) derepressed Enterobacter, and 1 VRE. The other 3069 MDRB were isolated from various sites, including respiratory samples and wounds, but it was not possible to differentiate between colonization and infection. No case of meningitis as a result of MDRB was recorded.


   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
CONCLUSIONS
 REFERENCES
 
The rate of nosocomial infections that are caused by MDRB is a good indicator of compliance with prevention control measures and antibiotic policy. It also is used to optimize the empiric treatment that is administered by clinicians. The incidence and bacterial epidemiology of nosocomial infections in children differ from those in adults, confirming the need for specific evaluation.14 MRSA strains are endemic in adults in many American and European hospitals, accounting for 5% to 65% in ICUs.5,6,17 Previous pediatric studies that included all hospitalized children have reported proportions of 18% to 27% for MRSA.2,18 However, the incidence of MRSA infection in children also was reported to be closer to that for adults (1.06 vs 0.81 per 1000 HD and 0.52 vs 0.63 per 100 admissions in 1999).14 As reported earlier for adults in other countries,19 we report here a significant decrease in the incidence per 1000 HD of MRSA during the 5-year period studied, contrasting with the increase in incidence, from 0.71 to 0.96 per 1000 HD in adults during the 1996–2001 period.14 The incidence per 100 admissions of MRSA decreased, but the proportion of MRSA was not significantly different from that in adults.14,19

Numerous outbreaks of ESBLKp have been reported in several countries in adults as well as in children.20–24 The prevalence of ESBLKp in adult patients is higher in Latin America (45%) and Europe (16.7% to 23%) than in the United States (8%).25–27 We found a higher proportion of ESBLKp in French children (23.2%) than in French adults (11.4%).14 However, incidence of ESBLKp decreased in all centers during the study period. Conversely, our results confirm those of Hernandez et al,27 who reported a low proportion and incidence of ESBLE infections in children, in contrast to recent data from the Microbiology Surveillance Network of Northern France for adult patients.14,28 This incidence decreased in all centers except 1, in which was reported a low number of strains. The low prevalence of VRE (1%) also was reported previously in adults in other studies in Europe (0%–0.3%) and France.18,29

In our study, trends in incidence per 100 admissions may have varied from center to center. When a decrease was observed in all centers for ESBLKp and derepressed E cloacae, incidence was more variable for MRSA. Therefore, it can be speculated that these findings may not be applicable to other metropolitan areas or other countries. Because this prospective study was conducted in the microbiology laboratories, data from PICUs and NICUs could not be differentiated from the pediatric units.

Antibiotic treatment may affect the incidence of infections that are caused by MDRB, MRSA, and Gram-negative bacilli.30 Colonization with resistant Gram-negative bacilli has been shown to be associated with the empiric use of amoxicillin and cefotaxime, leading to selection pressure that promotes ESBL-producing bacteria emergence.31 Cefotaxime use also may select Enterobacteriaceae with naturally derepressed cephalosporinase. Restriction of the antibiotic use can lead to a decrease in MDRB colonization.32,33 During the study, no changes in antimicrobial drug use, which could explain the MDRB decreased incidence, were observed in the various pediatric departments.

The major reservoir of MDRB is colonized/infected adult or pediatric patients. The hand carriage accounts for the major mechanism for patient-to-patient transmission.34 Wendt et al35 stated that bacterial overgrowth in the gut of patients in the ICU is a relevant mechanism to acquired carriage of MDRB during a nonoutbreak situation.35 Therefore, barrier precautions are important to avoid patient-to-patient transmission. The national guidelines, including recommendations similar to those of the US Hospital Infection Control Practices Advisory Committee, were distributed to all hospitals.36 However, no external audit was conducted to assess the validity of hygiene control procedures.

Methicillin-resistant coagulase-negative Staphylococcus, the pathogen that most commonly is responsible for systemic infection that is associated with a central venous catheter in children, was excluded from this analysis. The inclusion of methicillin-resistant coagulase-negative Staphylococcus in future studies of MDRB infections in children would be of clinical relevance.


   CONCLUSIONS
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 CONCLUSIONS
REFERENCES
 
The epidemiologic characteristics of MDRB differ in children and adults. We report in 5 pediatric centers a decrease in the frequency of MDRB isolation that needs to be confirmed. Evidence-based effective measures, including greater compliance with hand hygiene rules that are based on the use of alcohol-based hand rubs,37 restrictions on antibiotic use, early communication, and isolation, probably are effective in pediatric units, but additional prospective evaluations are required.


   FOOTNOTES
 
Accepted Oct 11, 2006.

Address correspondence to Josette Raymond, MD, PhD, Service de Bactériologie, Hôpital Cochin-Saint Vincent de Paul, 27 rue du faubourg Saint-Jacques, 75679 Paris Cedex 14, France. E-mail: j.raymond{at}svp.ap-hop-paris.fr

The authors have indicated they have no financial relationships relevant to this article to disclose.


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 CONCLUSIONS
 REFERENCES
 

  1. Ho PL, for the Hong Kong Intensive Care Unit Antimicrobial Resistance Study (HK-ICARE) Group. Carriage of methicillin-resistant Staphylococcus aureus, ceftazidime-resistant gram-negative bacilli, and vancomycin-resistant enterococci before and after intensive care unit admission. Crit Care Med. 2003;31 :1175 –1182[CrossRef][ISI][Medline]
  2. Raymond J, Aujard Y. Nosocomial infections in pediatric patients: a European, multicenter prospective study. European Study Group. Infect Control Hosp Epidemiol. 2000;21 :260 –263[CrossRef][ISI][Medline]
  3. Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol. 1996;17 :99 –104
  4. D'Agata E, Venkataraman L, DeGirolami P, et al. Colonization with broad-spectrum cephalosporin-resistant Gram-negative bacilli in intensive care units during a non outbreak period: prevalence, risk factors, and rate of infection. Crit Care Med. 1999;27 :1090 –1095[CrossRef][ISI][Medline]
  5. Tiemersma EW, Bronzwaer SL, Lyytikäinen O, et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis. 2004;10 :1627 –1634[ISI][Medline]
  6. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R, National Nosocomial Infections Surveillance System. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992–2003. Clin Infect Dis. 2006;42 :389 –391[CrossRef][ISI][Medline]
  7. Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997–1998. J Antimicrob Chemother. 2000;45 :183 –189[Abstract/Free Full Text]
  8. Lucet J, Chevret S, Decre D, et al. Outbreak of multiply resistant Enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis. 1996;22 :430 –436[ISI][Medline]
  9. Weinstein RA. Controlling antimicrobial resistance in hospitals: infection control and use of antibiotics. Emerg Infect Dis. 2001;7 :188 –192[ISI][Medline]
  10. Cosseron-Zerbib M, Roque Afonso AM, Naas T, et al. A control programme for MRSA (methicillin-resistant Staphylococcus aureus) containment in a pediatric intensive care unit: evaluation and impact infections caused by other micro-organisms. J Hosp Infect. 1998;40 :225 –235[CrossRef][ISI][Medline]
  11. Kim YK, Pai H, Lee HJ, et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother. 2002;46 :1481 –1491[Abstract/Free Full Text]
  12. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter related-infections. Clin Infect Dis. 2001;32 :1249 –1272[CrossRef][Medline]
  13. Eisenstadt J, Washington JA. Diagnostic microbiology for bacteria and yeasts causing urinary tract infections. In: Mobley HLT, Warren JW, eds. Urinary Tract Infections. Washington, DC: ASM Press; 1996:29 –67
  14. The Microbiology Surveillance Network of Northern France. Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended-spectrum ß-lactamase (ESBLE) in Northern France: a five-year multicenter incidence study. J Hosp Infect. 2002;52 :107 –113[CrossRef][ISI][Medline]
  15. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard M7-A5. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000
  16. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis. 1988;10 :867 –878[ISI][Medline]
  17. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339 :520 –552[Free Full Text]
  18. Branger B, Comité technique des infections nosocomiales (CTIN) et le Réseau d'alerte d'investigation et de surveillance des infections nosocomiales (RAISIN) avec les centres de coordination des comités de lutte contre les infections nosocomiales (C.CLIN). A one-day nosocomial infections prevalence survey among newborns and under-eighteen children in France [in French]. Arch Pediatr. 2005;12 :1085 –1093[CrossRef][ISI][Medline]
  19. Struelens MJ, Ronveaux O, Jans B, Mertens R. Methicillin-resistant Staphylococcus aureus epidemiology and control in Belgian hospitals, 1991 to 1995. Groupement pour le Dépistage, l'Etude et la Prévention des Infections Hospitalières. Infect Control Hosp Epidemiol. 1996;17 :503 –508[ISI][Medline]
  20. Kim J, Kwon Y, Pai H, Kim JW, Cho DT. Survey of Klebsiella pneumoniae strains producing extended-spectrum ß-lactamases: prevalence of SHV-12 and SHV-2a in Korea. J Clin Microbiol.36 :1446 –1449
  21. Bagattini M, Crivaro V, Di Popolo A, et al. Molecular epidemiology of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit. J Antimicrob Chemother. 2006;57 :979 –982[Abstract/Free Full Text]
  22. Brinas L, Lantero M, Zarazaga M, Perez F, Torres C. Outbreak of SHV-5 beta-lactamase-producing Klebsiella pneumoniae in a neonatal-pediatric intensive care unit in Spain. Microb Drug Resist. 2004;10 :354 –358[CrossRef][ISI][Medline]
  23. Miranda G, Castro N, Leanos B, et al. Clonal and horizontal dissemination of Klebsiella pneumoniae expressing SHV-5 extended-spectrum beta-lactamase in a Mexican pediatric hospital. J Clin Microbiol. 2004;42 :30 –35[Abstract/Free Full Text]
  24. Branger C, Lesimple AL, Bruneau B, Berry P, Lambert-Zechovsky N. Long-term investigation of the clonal dissemination of Klebsiella pneumoniae isolates producing extended-spectrum ß-lactamases in a university hospital. J Med Microbiol. 1998;47 :201 –219[Abstract]
  25. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum ß-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis. 2001;32 (suppl 2):S94–S103
  26. Jarlier V, Fosse T, Philippon A. Antibiotic susceptibility in aerobic gram-negative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study). Intensive Care Med. 1996;22 :1057 –1065[ISI][Medline]
  27. Hernandez JR, Pascual A, Canton R, Martinez-Martinez I, Grupo de Estudio de Infeccion Hospitalaria. GEIH. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals (GEIH-BLEE Project 2002) [in Spanish]. Enferm Infecc Microbiol Clin. 2003;21 :77 –82[CrossRef][ISI][Medline]
  28. Tonkic M, Goic-Barisic I, Punda-Polic V. Prevalence and antimicrobial resistance of extended-spectrum beta-lactamases-producing Escherichia coli and Klebsiella pneumoniae strains isolated in a university hospital in Split, Croatia. Int Microbiol. 2005;8 :119 –124[ISI][Medline]
  29. Schouten MA, Hoogkamp-Korstanje JA, Meis JF, Voss A, European VRE Study Group. Prevalence of vancomycin-resistant enterococci in Europe. Eur J Clin Microbiol Infect Dis. 2000;19 :816 –822[CrossRef][ISI][Medline]
  30. Crowcroft NS, Ronveaux O, Monnet DL, Mertens R. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol. 1999;20 :31 –36[CrossRef][ISI][Medline]
  31. De Man P, Verhoeven BA, Verbrugh HA, Vos MC, Van den Anker JN. An antibiotic policy to prevent emergence of resistant bacilli. Lancet. 2000;355 :973 –978[CrossRef][ISI][Medline]
  32. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115 :585 –590[ISI][Medline]
  33. Calil R, Marba ST, von Nowakonski A, Tresoldi AT. Reduction in colonization and nosocomial infection by multiresistant bacteria in a neonatal unit after institution of educational measures and restriction in the use of cephalosporins. Am J Infect Control. 2001;29 :133 –138[CrossRef][ISI][Medline]
  34. Haddadin AS, Fappiano SA, Lipsett PA. Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad Med J. 2002;78 :385 –392[Abstract/Free Full Text]
  35. Wendt C, Lin D, von Baum H. Risk factors for colonization with third-generation cephalosporin-resistant Enterobacteriaceae. Infection. 2005;33 :327 –332[CrossRef][ISI][Medline]
  36. Guideline for isolation precautions in hospitals. Part II. Recommendations for isolation precautions in hospitals. Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1996;24 :32 –52
  37. Weinstein RA. Controlling antimicrobial resistance in hospitals: infection control and use of antibiotics. Emerg Infect Dis. 2001;2 :188 –192[Medline]
PEDIATRICS (ISSN 1098-4275). ©2007 by the American Academy of Pediatrics




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raymond, J.
Right arrow Articles by Aujard, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raymond, J.
Right arrow Articles by Aujard, Y.
Related Collections
Right arrow Infectious Disease & Immunity